Constitutive Activation of Activin Receptor-like Kinase 2 in Human Breast Cancer Cells inhibits Metastatic Progression and Osteolytic Bone Lesions
Maj Petersen,Jeroen T. Buijs,Evangelia Pardali,Geertje van der Horst,Henry Cheung,Peter ten Dijke,Gabri van der Pluijm
2010-01-01
Abstract:Transforming growth factor-β (TGF-β) is a crucial player in metastasis of breast cancer cells to bone. We previously reported that bone morphogenetic protein-7 (BMP-7) can counteract the effects of TGF-β in vitro and inhibit the progression and formation of osteotropic MDA-BO2 human breast cancer bone metastasis in vivo. Whether BMP-7 acts directly on the breast cancer cells and/or on the cancer-associated bone stroma has remained elusive. Here, we demonstrated that activin-like kinase receptor 2 (ALK2) is the functional BMP-7 type I receptor in MDA-BO2 cells. Subsequently, to restrict BMP7-induced actions to MDA-BO2 cells we engineered these cells to ectopically express a constitutively active variant of ALK2, denoted caALK2. We demonstrate that caALK2 continuously activates the BMP signaling pathway as measured by Smad phosphorylation, BMP transcriptional reporter activity and target gene responses, and antagonized basal and TGF-β-induced transcriptional reporter activation. In vivo tumor-induced osteolysis and metastatic progression was mitigated in mice inoculated with MDA-BO2 cells overexpressing caALK2 compared to a control cell line. These observations suggest that cell autonomous activation of caALK2 or BMP7 over-expression in breast tumor cells inhibit osteolysis and metastatic progression possibly by interfering with the TGF-β-mediated self-amplifying cycle of bone destruction. Abbreviations ActR-II, Activin receptor type II; ALK, Activin receptor-like kinase; caALK, constitutively active ALK; BMP, bone morphogenetic protein; BMPR-II, BMP receptor type II; BRE, BMPresponsive element; caALK2, constitutively active ALK2; EMT, epithelial mesenchymal transition; GFP, green fluorescent protein; HLH, helix-loop-helix; ID, inhibitor of differentiation/DNA binding; μ-CT, micro-computed tomography; MET, mesenchymal epithelial transition; P-Smad, phosphorylated Smad; I-Smad, inhibitory Smad; Smad, small phenotype and mothers against DPP related protein; TGF-β, transforming growth factor β.